May-Tal Sauerbrun-Cutler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
May-Tal Sauerbrun-Cutler has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Caroline J. Violette
3 shared publications- Jennifer L. Eaton
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Women and Infants Hospital and Warren Alpert Medical School of Brown University, Providence, Rhode Island
2 shared publications - Alexis Gadson
Shady Grove Fertility Center, Rockville, MD 20850, USA
1 shared publication - Alexis K. Gadson
Shady Grove Fertility
1 shared publication - Allegra Rollo
Brown University Warren Alpert Medical School
1 shared publication Chloe Shen
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 plain street, Providence, RI, 02905, USA
1 shared publication
Latest Publications
- 3 September 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 126 (5) , 950-951
Similar yield, different circumstances: oocyte yield holds steady across elective and oncofertility cycles
- 3 September 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 126 (5) , 950-951
Similar yield, different circumstances: oocyte yield holds steady across elective and oncofertility cycles
- 2 January 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 125 (3) , 427-428
Revisiting oncofertility outcomes: what the Society for Assisted Reproductive Technology can and cannot tell us about cryopreserved oocyte utilization
- 2 January 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 125 (3) , 427-428
Revisiting oncofertility outcomes: what the Society for Assisted Reproductive Technology can and cannot tell us about cryopreserved oocyte utilization
- 5 December 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 125 (2) , 273-274
Pelvic organ transposition: fertility preservation promise or premise?
- 5 December 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 125 (2) , 273-274
Pelvic organ transposition: fertility preservation promise or premise?
- 2 September 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (6) , 1219-1220
Age, antimüllerian hormone, and oocyte yield: progress in prediction for elective oocyte cryopreservation
- 2 September 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (6) , 1219-1220
Age, antimüllerian hormone, and oocyte yield: progress in prediction for elective oocyte cryopreservation
- 4 November 2024
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 51 (2) , 104699
Do aromatase inhibitors and tamoxifen affect oocyte numbers retrieved in oocyte or embryo banking cycles?
- 4 November 2024
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 51 (2) , 104699
Do aromatase inhibitors and tamoxifen affect oocyte numbers retrieved in oocyte or embryo banking cycles?
- Open Access
- 14 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1072
The Status of Fertility Preservation (FP) Insurance Mandates and Their Impact on Utilization and Access to Care
Fertility preservation (FP) is the use of a specific medical intervention to protect the fertility of individuals whose disease or disease treatment may lead to infertility. These medical interventions include the cryopreservation of oocytes, embryos, ovarian tissue, sperm, and testicular tissue; oocyte and embryo cryopreservation are the most widely used interventions in the United States. Although guidelines recommend FP prior to undergoing gonadotoxic treatments, cost barriers are high. For example, the average cost of an oocyte cryopreservation cycle in the United States exceeds $10,000. High cost and lack of insurance coverage are two of the most cited reasons explaining the low Reproductive Endocrinology and Infertility (REI) referral rates and limited FP utilization. Broadening insurance mandates for FP prior to gonadotoxic treatments could improve utilization and provide cancer survivors with improved quality of life post treatment.
- 14 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1072
Open AccessThe Status of Fertility Preservation (FP) Insurance Mandates and Their Impact on Utilization and Access to Care
Fertility preservation (FP) is the use of a specific medical intervention to protect the fertility of individuals whose disease or disease treatment may lead to infertility. These medical interventions include the cryopreservation of oocytes, embryos, ovarian tissue, sperm, and testicular tissue; oocyte and embryo cryopreservation are the most widely used interventions in the United States. Although guidelines recommend FP prior to undergoing gonadotoxic treatments, cost barriers are high. For example, the average cost of an oocyte cryopreservation cycle in the United States exceeds $10,000. High cost and lack of insurance coverage are two of the most cited reasons explaining the low Reproductive Endocrinology and Infertility (REI) referral rates and limited FP utilization. Broadening insurance mandates for FP prior to gonadotoxic treatments could improve utilization and provide cancer survivors with improved quality of life post treatment.
- Open Access
- 13 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1060
Racial Disparities in Fertility Care: A Narrative Review of Challenges in the Utilization of Fertility Preservation and ART in Minority Populations
Significant ethnic and racial disparities exist in the utilization and outcomes of assisted reproductive technology (ART) in the United States. The popularity of fertility preservation (FP) procedures, a specific application of ART for those desiring to delay childbearing, has increased; however, many minority populations have seen a less rapid uptake of these services. Minority patients pursuing ART are more likely to have poorer in vitro fertilization (IVF) and pregnancy outcomes. These outcomes are used to predict success after FP and may lessen the appeal of such procedures in these populations. Suboptimal outcomes are further compounded by challenges with receiving referrals to, accessing, and paying for FP services. Resolving these disparities in minority populations will require culturally appropriate education surrounding the benefits of ART and FP, the demonstration of favorable outcomes in ART and FP through continued research engaging minority participants, and continued advocacy for expanded access to care for patients.
- 13 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1060
Open AccessRacial Disparities in Fertility Care: A Narrative Review of Challenges in the Utilization of Fertility Preservation and ART in Minority Populations
Significant ethnic and racial disparities exist in the utilization and outcomes of assisted reproductive technology (ART) in the United States. The popularity of fertility preservation (FP) procedures, a specific application of ART for those desiring to delay childbearing, has increased; however, many minority populations have seen a less rapid uptake of these services. Minority patients pursuing ART are more likely to have poorer in vitro fertilization (IVF) and pregnancy outcomes. These outcomes are used to predict success after FP and may lessen the appeal of such procedures in these populations. Suboptimal outcomes are further compounded by challenges with receiving referrals to, accessing, and paying for FP services. Resolving these disparities in minority populations will require culturally appropriate education surrounding the benefits of ART and FP, the demonstration of favorable outcomes in ART and FP through continued research engaging minority participants, and continued advocacy for expanded access to care for patients.
- 17 June 2023
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 40 (8) , 2003-2011
Survey of young women with breast cancer to identify rates of fertility preservation (FP) discussion and barriers to FP care
Purpose To identify the proportion of reproductive age women with breast cancer that engaged in a fertility preservation discussion and reproductive endocrinology and infertility (REI) consultation. Methods This cross-sectional survey recruited women 18–42 years who were diagnosed with breast cancer from 2006 to 2016 by phone or email and asked them to complete an online survey. Demographic characteristics, barriers to FP, utilization of FP consultation, and FP procedures (oocyte and embryo cryopreservation) were analyzed. Results A majority of women (64%) did not have FP discussed by any provider. Older women and those who were parents at the time of diagnosis were less likely to engage in a FP discussion. However, there were no significant differences in partner status or cancer stage between women with or without FP discussions. Of the women who desired future children prior to the cancer diagnosis, 93% received chemotherapy; however, only 34% of these women had a consultation with an REI. The most common reasons for declining FP consultation were already having their desired number of children (41%), financial barriers (14%), and concern about delaying cancer treatment and cancer recurrence (12%). Forty percent of women who desired future children and met with an REI pursued FP procedures. Conclusion Younger women were more likely to receive FP counseling. FP consultations and procedures were low even in women who desired future fertility, with the predominant barriers being cost, fears concerning a delay in cancer treatment, and future cancer recurrence.
- 17 June 2023
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 40 (8) , 2003-2011
Survey of young women with breast cancer to identify rates of fertility preservation (FP) discussion and barriers to FP care
Purpose To identify the proportion of reproductive age women with breast cancer that engaged in a fertility preservation discussion and reproductive endocrinology and infertility (REI) consultation. Methods This cross-sectional survey recruited women 18–42 years who were diagnosed with breast cancer from 2006 to 2016 by phone or email and asked them to complete an online survey. Demographic characteristics, barriers to FP, utilization of FP consultation, and FP procedures (oocyte and embryo cryopreservation) were analyzed. Results A majority of women (64%) did not have FP discussed by any provider. Older women and those who were parents at the time of diagnosis were less likely to engage in a FP discussion. However, there were no significant differences in partner status or cancer stage between women with or without FP discussions. Of the women who desired future children prior to the cancer diagnosis, 93% received chemotherapy; however, only 34% of these women had a consultation with an REI. The most common reasons for declining FP consultation were already having their desired number of children (41%), financial barriers (14%), and concern about delaying cancer treatment and cancer recurrence (12%). Forty percent of women who desired future children and met with an REI pursued FP procedures. Conclusion Younger women were more likely to receive FP counseling. FP consultations and procedures were low even in women who desired future fertility, with the predominant barriers being cost, fears concerning a delay in cancer treatment, and future cancer recurrence.
- 9 December 2022
- Published by Elsevier in Fertility and Sterility
- Vol. 119 (2) , 300
Does assisted reproductive technology increase risk of multiple sclerosis?
- 9 December 2022
- Published by Elsevier in Fertility and Sterility
- Vol. 119 (2) , 300
Does assisted reproductive technology increase risk of multiple sclerosis?
- 29 September 2022
- Published by Elsevier in Fertility and Sterility
- Vol. 118 (4) , 713-714
The progestin-primed ovarian stimulation protocol: more economical, but at what cost?
- 29 September 2022
- Published by Elsevier in Fertility and Sterility
- Vol. 118 (4) , 713-714
The progestin-primed ovarian stimulation protocol: more economical, but at what cost?